Lexicon Pharmaceuticals (LXRX) Total Debt (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Total Debt of $49.7 million for Q1 2026, down 50.66% year-over-year from $100.7 million in Q1 2025, and down 8.0% quarter-over-quarter from $54.0 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Total Debt (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Total Debt for 17 consecutive years, with $49.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt fell 50.66% year-over-year to $49.7 million; the TTM figure through Mar 2026 stood at $49.7 million (down 50.66% YoY), while the FY2025 annual figure was $54.0 million, down 46.16% from the prior year.
- Total Debt slipped to $49.7 million in Q1 2026 per LXRX's latest filing, from $54.0 million in the prior quarter.
- Across five years, Total Debt topped out at $100.7 million in Q1 2025 and bottomed at $23.5 million in Q1 2022.
- Historically, Total Debt has averaged $69.6 million across 5 years, with a median of $56.5 million in 2025.
- Annual changes were most pronounced in 2023 — Total Debt soared 318.64% — and 2026, when it sank 50.66%.
- Lexicon Pharmaceuticals' Total Debt stood at $48.6 million in 2022, then surged by 104.84% to $99.5 million in 2023, then rose by 0.79% to $100.3 million in 2024, then tumbled by 46.16% to $54.0 million in 2025, then retreated by 8.0% to $49.7 million in 2026.
- Business Quant data shows LXRX's Total Debt at $49.7 million in Q1 2026, $54.0 million in Q4 2025, and $56.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 51.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.44 Mn |
| Mar 31, 2026 | 49.68 Mn |
| Dec 31, 2025 | 54.00 Mn |
| Sep 30, 2025 | 56.51 Mn |
| Jun 30, 2025 | 56.10 Mn |
| Mar 31, 2025 | 100.70 Mn |
| Dec 31, 2024 | 100.30 Mn |
| Sep 30, 2024 | 99.90 Mn |
| Jun 30, 2024 | 99.50 Mn |
| Mar 31, 2024 | 99.90 Mn |
| Dec 31, 2023 | 99.51 Mn |
| Sep 30, 2023 | 99.27 Mn |
| Jun 30, 2023 | 98.80 Mn |
| Mar 31, 2023 | 48.80 Mn |
| Dec 31, 2022 | 48.58 Mn |
| Sep 30, 2022 | 23.78 Mn |
| Jun 30, 2022 | 23.60 Mn |
| Mar 31, 2022 | 23.48 Mn |
| Sep 30, 2021 | 11.69 Mn |
| Jun 30, 2021 | 11.68 Mn |